anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention includes compounds, methods of making, and methods of using the same. The compounds of the invention are linear or cyclic having a central backbone and three or four additional functional groups: one or two lipophilic compounds include sterols, fat soluble vitamins, one or two hydrophilic high molecular polymers, and one or two carbohydrates. The present invention discloses a class of polymer-carbon compound conjugates having a central backbone and three additional functional groups wherein lipophilic compounds preclude the use of steroid acids. The conjugate may have a fatty acid as the primary lipophilic carrier, a hydrophilic high molecular weight polymer and a carbohydrate. The specific functional group can be selectively applied to the fields of medicines, cosmetics, nutriments and the like. Typical coupling reactions of conjugates can be achieved via one or more types of reactions or chemistry combined with multiple or tandem alkylation reactions including N-or O-alkylation, etherification, esterification, and amidation. Various linking groups between the central backbone and the carrier may also be selected to modify the central backbone to facilitate its coupling reaction and to optimize the performance of the conjugate.
An automated method for the handling of information sharing requests involves a step of classifying fields in an Institutional Information database that contain Information data as Confidential Information fields and Non-confidential Information fields. A further step involves programming a computer processor with criterion for the release of information. A final step involves programming the computer processor to respond to an automated Request for Information. The computer processor starts by computing which of the searchable fields in the Institutional Information Database are applicable to the Request for Information. The computer processor then applies the criterion for the release of information to each of the applicable searchable fields. The computer processor then issues an automated acceptance for the release of information in those searchable fields for which the applicable criterion are met, along with a report listing those searchable fields for which the applicable criterion have not been met.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, sensorimotor polyneuropathy. It has presented with a variety of orbital and neuro-ophthalmic manifestations, including cranial nerve hypertrophy and a single case of extraocular muscle enlargement. The authors present a second case of tendon-sparing, extraocular muscle enlargement, resulting in new-onset diplopia and strabismus in a teenager with CIDP. The workup ruled out alternative causes of extraocular muscle enlargement, such as hyperthyroidism, inflammation, or malignancy. As with other cases of CIDP, management involved a combination of immunoglobulin therapy and anti-inflammatory medications. The patient experienced resolution of his symptoms, and radiologic improvement was noted in the muscle enlargement. As many CIDP patients have a favorable treatment response and long-term prognosis, awareness of this rare disease with an early and accurate diagnosis is important.
A system and method for developing a pharmacovigilance database from source data and reference data. The unedited source data contains verbatim terms. The method includes parsing source data into a relational safety database; performing cleanup on the relational safety database; and mapping verbatim terms from the cleaned safety database to at least one token from at least one reference source. Cleanup includes removing redundant entries, correcting misspellings, removing irrelevant non-alpha characters and noise words, and relocating dislocated terms. Mapping verbatim terms to tokens includes nominating tokens from the source data, choosing tokens from the reference sources, and linking chosen tokens to corresponding verbatim terms. In one embodiment, the history of clean-up and mapping is saved as the pedigree of the verbatim-to-token mapping.
To provide efficient methods for identifying biomarkers.SOLUTION: A method can include a step of identifying a tumor area. The method may further include a step of identifying a plurality of regions. The method may also include a step of defining, for each region, a bounding area for the region that encompasses the region. The method may include a step of determining, for each region of a first subset of the plurality of regions, that the region is to be ascribed to the tumor, where the bounding area is fully within the tumor area. The method may further include a step of determining, for each region of a second subset of the plurality of regions, whether or not to ascribe the region to the tumor based on an intersection of the region and the tumor area. The method may also include a step of accessing a metric characterizing a biological observation and a step of generating a result based on the metrics. The result may be used as a biomarker.SELECTED DRAWING: Figure 2
In sequence 1, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 under fasting condition (Treatment A), followed by single dose of GSK5464714 in fed condition (Treatment B). There will be a washout period of minimum 7 days between each period.
Assess blood counts and blood chemistries prior to the initiation of TIBSOVO, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy. Monitor blood creatine phosphokinase weekly for the first month of therapy. Monitor electrocardiograms (ECGs) at least once weekly for the first 3 weeks of therapy and then at least once monthly for the duration of therapy. Manage any abnormalities promptly [see Adverse Reactions (6.1)].

Interrupt dosing or reduce dose for toxicities. See Table 1 for dose modification guidelines.
The present invention provides an IgM antibody for use in a method for treatment or 5 diagnosis of a disease in a subject. The subject especially but not exclusively is a human and the disease includes cancer, an infectious disease, an autoimmune disease or an allergic disease. In another aspect, the present invention refers to a pharmaceutical composition for use in a method for treatment of a disease and a kit for diagnosis of a disease in a subject such as in a human comprising the IgM antibody. 10 The inventor unexpectedly found that the IgM antibodies are highly advantageous over IgG antibodies of at least similar specificity which cannot access the target antigen and, thus, fail to sufficiently treat or diagnose the disease. 9270519_1 (GHMatters) P106323.AU Antibody combining site Antigen Fc Light chain 4- Heavy chain Fig. 1A Fig. 1B 1gM ~ilsomerize IgG naked antigen blocked antigen blocked antigen blocked antigen Fig. 1C
BACKGROUND: Fractures of the distal radius in childhood are frequent but rarely lead to relevant growth disturbances.
OBJECTIVE: The experiences of a pediatric trauma center over 15 years are exemplarily presented and discussed.
MATERIAL AND METHODS: Osteotomies of the distal radius were selected and the clinical and radiological findings were recorded and analyzed.
RESULTS: Posttraumatic growth disturbances were corrected in 10 cases with a median age of 13 ½ years. In six cases an iatrogenic cause was also possible. In two cases callus distraction with secondary palmar plate osteosynthesis was used for consolidation. In eight cases primary ad hoc corrections were carried out using palmar plate osteosynthesis (six with iliac crest and two with allogeneic grafts). In five cases the distal ulnar growth plate was also addressed. During follow-up breakage of one plate was registered. After an average of 31 months postoperatively, 9 children had full range of motion (ROM) and in 1 case there was an extension deficit of 10o.
CONCLUSION: It is important to evaluate the cause of the mostly partially inhibiting growth disturbances to draw preventive conclusions. From a clinical perspective the visible deformity is given priority and the pain and functional limitations are less relevant. The indications for corrective surgery must include the age of the patient, remaining growth potential, size and localization of the growth plate bridge, the deformity and the individual wishes of patients and parents. In most cases a full correction is possible with palmar plate osteosynthesis and an iliac crest graft. External fixation and callus distraction is an alternative in cases where the correction is more extensive. The distal ulnar growth plate should be controlled concerning further growth potential before hardware removal.
The invention discloses a traditional Chinese medicine composition for treating rheumatism. The medicine is characterized by being prepared from the following raw materials, by weight part: 25-35 of radix astragali, 25-35 of Chinese peony, 25-35 of cinnamon twigs, 50-70 of ginger, 10-20 of red dates, 5-15 of rhizoma ligustici chuanxiong, 15-25 of curcuma wenyujin rhizome, 2-5 of honey-fried licorice roots, 5-15 of radix clematidis, and 5-15 of as arum. The raw materials are decocted with water. In the composition, ten natural traditional Chinese medicines are selected for scientific matching, and the formula is simple. The raw herbs have a synergistic effect, have the efficacy of clearing heat and detoxifying the body, dispelling wind and arresting convulsions, and relieving pains, and have a quick curative effect. Both symptoms and root causes can be treated, and the composition has no toxic or side effect. The composition is simple in preparation method, convenient to take, and low in cost, and the effective rate can reach more than 95%.
OTAGO program - based on very specific exercises for balance, force, and muscular endurance as well as on education about the risk of falling. The program is considered as "home care" (exercises to be done at home) but will be done as a group and with supervision, at CIUSSS or from outdoor and nature intervention (recreactional parks). OTAGO session lasts for 30-40 minutes and will be done twice a week at sites with progression. The program is comprised of 5 muscle strengthening exercises and 12 postural balance exercises. Participants will also be invited to walk 2 times per week for 30 minutes (can be divided into shorter periods, for example 3 blocs of 10 minutes) from outdoor sites or recrative parks. According to each person's strength and mobility, exercises will be increased with the use of free weights (for example during squats) and/or by increasing the number of repetitions. Total duration of the program will be 3 months (i.e., a duration adapted to the site).
BACKGROUNDS AND AIMS: Reports on cross-sectional and longitudinal associations between health-related quality of life (HRQoL), psychological distress, and irritable bowel syndrome (IBS) in the adolescent and young adult general population are few. We aimed to describe cross-sectional associations between HRQoL and IBS in adolescence and young adulthood, and examine bidirectional gut-brain interactions in the transition from childhood to adulthood.
METHODS: We included 3391 subjects from a prospective birth cohort study, with data on IBS at 16 years of age and 24 years of age. IBS was assessed using the pediatric Rome III (16 years of age) and the adult Rome IV (24 years of age) diagnostic questionnaires. HRQoL and psychological distress were assessed through EQ-5D. Sex-adjusted logistic regression models were used to examine associations between overall HRQoL/psychological distress at 16 years of age and new-onset IBS at 24 years of age (brain-gut) and between IBS at 16 years of age and new-onset psychological distress at 24 years of age (gut-brain).
RESULTS: In subjects with vs without IBS at 16 and 24 years of age, overall HRQoL (EQ visual analog scale, EQ-5D index value) was lower, and it was more common reporting problems in 4 of 5 EQ-5D dimensions (all P < .05). EQ-5D index value at 16 years of age was inversely associated (odds ratio [OR], 0.1, 95% confidence interval [CI], 0.01-0.6), and psychological distress at 16 years of age was positively associated (OR, 1.6; 95% CI, 1.2-2.3), with new-onset IBS at 24 years of age. Having any abdominal pain-related disorder of gut-brain interaction at 16 years of age was associated with new-onset psychological distress at 24 years of age (OR, 1.7; 95% CI, 1.2-2.5).
CONCLUSIONS: Adolescents and young adults with IBS in the general population have impaired HRQoL. Bidirectional gut-brain interactions are relevant for symptom generation in abdominal pain-related disorders of gut-brain interaction, and for HRQoL impairment and psychological distress in the transition from childhood to adulthood.
VIGAFYDE is indicated for treatment in patients 1 month to 2 years of age [see Indications and Usage (1)]. VIGAFYDE is not approved for use in adolescents and adults.

Risk Summary   
Vigabatrin is excreted in human milk. The effects of vigabatrin on the breastfed infant and on milk production are unknown. Because of the potential for serious adverse reactions from vigabatrin in nursing infants, breastfeeding is not recommended. If exposing a breastfed infant to VIGAFYDE, observe for any potential adverse effects [see Warnings and Precautions (5.1, 5.3, 5.4, 5.8)].
Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 1-2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
BACKGROUND: Benign biliary disease (BBD) is a prevalent condition involving patients who require extrahepatic bile duct resections and reconstructions due to nonmalignant causes.
METHODS: This study followed all patients who underwent biliary resections for BBD between 2015 and 2023. We excluded those with malignant conditions and patients who had an 'open' operation. Based on the patient's anatomy, the procedures employed were either robotic Roux-en-Y hepaticojejunostomy (RYHJ) or robotic choledochoduodenostomy (CDD).
RESULTS: From the 33 patients studied, 23 were female, and 10 were male. Anesthesiology (ASA) class was 3 ± 0.5; the MELD score was 9 ± 4.1; the Child-Pugh score was 6 ± 1.7. The primary indications for undergoing the operation included iatrogenic bile duct injuries, biliary strictures, and type 1 choledochal cysts. The average surgical duration was about 272 min, and the average blood loss amounted to 79 mL. Postoperatively, three patients experienced major complications, all attributed to anastomotic leaks. The average hospital stay was 4 days, with a readmission rate of 15% within 30 days. During an average follow-up period of 33 months, one patient had to undergo a revision at 18 months due to stricture. This necessitated further duct resection and reanastomosis. Notably, there were no reported hepatectomies, no conversion to the 'open' method, no intraoperative complications, and no mortalities.
CONCLUSIONS: Robotic extrahepatic bile duct resection and reconstruction with Roux-en-Y hepaticojejunostomy or choledochoduodenostomy is safe with an acceptable postoperative morbidity, short hospital length of stay, and low postoperative stricture rate at intermediate duration follow-up.
This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
PREPARATIVE REGIMEN\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
Systems, methods, and computer-readable media determine a representative series using multiple time series of glucose readings. Systems may comprise one or more processors ("processing") and one or more computer-readable data storages (CRDS) storing instructions that, when executed by processing, cause processing to perform steps of the method. Some embodiments include one or more CRDS storing instructions for the methods that may be executed by one or more processors. Methods may comprise one or more processors receiving multiple time series in which each of the time series comprises glucose readings associated with respective timestamps. The time series may be generated during respective time periods. The one or more processors may adaptively determine a gamma parameter and determine a barycenter using the multiple time series and the gamma parameter. The one or more processors may apply a smoothing function to the barycenter yielding the representative series.
Despite the evidence for the beneficial effects of thiopurine/IFX combined therapy on both the prevention of the development of anti-IFX antibodies (ATI) and improved clinical outcomes, no study has employed the proven clinical usefulness of measuring 6- MP metabolite levels. We hypothesize that targeting the established threshold of 6-TGN levels (between 235-400), shown to result in superior clinical efficacy, would reduce the development of ATI and enhance trough IFX levels. It is also conceivable that excessive6TGN levels may increase the risk of adverse events such as infections and neoplasms such as lymphomas, the major drawbacks to combination therapy. If a significant correlation between 6-TGN levels and diminished risk of ATI development or higher trough serum IFX levels can be demonstrated, it will allow for an improved approach towards pharmacological monitoring of these patients with optimization of the long term response of CD patients on anti-TNF therapy.

Vitamin D possesses profound immunomodulatory effects, mediated primarily through the innate immune system. Low serum levels of vitamin D are associated with worse outcomes in CD. IFX was reported to have a significant impact on maturation and phenotype of dendritic cells (DC). Previous work from our laboratory demonstrated a significant effect of vitamin D on expression of NOD2 along with a profound effect onthe cytokine profile of DC exposed to PRR stimulation85. We hypothesize that vitamin Ddeficiency may be associated with a lower clinical response to anti-TNF therapy. IFX and vitamin D may have a synergistic effect in modulating the immune system in IBD via interactions through innate or adaptive mechanisms. We expect that vitamin D may enhance IFX-induced shift in the maturation pathway and cytokine profile of DC exposed to intestinal microbes through pattern recognition receptors (PRR). Demonstration of a synergistic effect of vitamin D with anti-TNF antibodies may have important clinical implications for the care of IBD patients, particularly in Canada where the prevalence of vitamin D deficiency is very high. Such an effect was demonstrated for lymphocytes but was never examined for the innate immune system, considered to have a profound role in the pathogenesis of CD. The data from this study may provide further justification for the need of monitoring vitamin D status in CD patients, and its supplementation as an additional therapeutic tool for optimizing response to anti-TNF in CD.

This is a prospective cross-sectional and longitudinal multicentre non-interventional study. The patients will be recruited at the following centers: McGill University Health Center, Mount Sinai Medical Centre, Toronto, Canada; University of Calgary, U Alberta, Edmonton. This study will recruit patients (18-70 yrs) with Crohn's disease who are starting treatment with infliximab or combo therapy of infliximab and azathiopurine. This study will look at therapeutic monitoring end points to evaluate the impact of drug level and antibodies on the clinical effectiveness of treatment (mono or combo therapy). .
PCT No. PCT/JP96/00268 Sec. 371 Date Dec. 9, 1997 Sec. 102(e) Date Dec. 9, 1997 PCT Filed Feb. 8, 1996 PCT Pub. No. WO97/28807 PCT Pub. Date Aug. 14, 1997The present invention is aimed at providing an anticancer agent which can inhibit the metastasis of cancer cells when used alone. In addition, the present invention is also aimed at providing an anticancer agent which can inhibit the metastasis of cancer cells while causing a small side effect and very small toxicity even for an extended time of administration. The cancer metastasis-inhibiting anticancer agent according to the present invention is characterized by containing sialic acid, its salt, a polymer of sialic acid or a salt of the polymer as an effective ingredient.
In the pathogenesis of microglia, brain immune cells promote nitrergic stress by overproducing nitric oxide (NO), leading to neuroinflammation. Furthermore, NO has been linked to COVID-19 progression, which has caused significant morbidity and mortality. SARS-CoV-2 infection activates inflammation by releasing excess NO and causing cell death in human microglial clone 3 (HMC3). In addition, NO regulates lysosomal functions and complex machinery to neutralize pathogens through phagocytosis. Therefore, developing lysosome-specific NO probes to monitor phagocytosis in microglia during the COVID-19 infection would be a significant study. Herein, a unique synthetic strategy was adopted to develop a NO selective fluorescent probe, PDM-NO, which can discriminate activated microglia from their resting state. The nonfluorescent PDM-NO exhibits a turn-on response toward NO only at lysosomal pH (4.5-5.5). Quantum chemical calculations (DFT/TD-DFT/PCM) and photophysical study revealed that the photoinduced electron transfer (PET) process is pivotal in tuning optical properties. PDM-NO demonstrated good biocompatibility and lysosomal specificity in activated HMC3 cells. Moreover, it can effectively map the dynamics of lysosomal NO against SARS-CoV-2 RNA-induced neuroinflammation in HMC3. Thus, PDM-NO is a potential fluorescent marker for detecting RNA virus infection and monitoring phagocytosis in HMC3.
Porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), and swine acute diarrhea syndrome coronavirus (SADS-CoV) cause intestinal diseases with similar manifestations in suckling piglets. In this study, we developed a multiplex real-time PCR for differential diagnosis of PEDV, PDCoV, and SADS-CoV. The assay demonstrated high specificity with a detection limit of 5 copies/µl for each virus. The assay specifically detected PEDV, PDCoV, and SADS-CoV and excluded all other swine pathogens circulating in pigs. Furthermore, the assay exhibited satisfactory performance in analyzing clinical samples. The data indicate that the newly developed multiplex real-time PCR method can be applied for differential diagnosis of porcine enteric coronaviruses.